Travere Therapeutics, Inc. (TVTX)
NGM – Real vaqt narxi. Valyuta: USD
42.84
-0.67 (-1.54%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Find any stock by ticker or company name

NGM – Real vaqt narxi. Valyuta: USD
42.84
-0.67 (-1.54%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Travere Therapeutics, Inc., biotexnika kompaniyasi, Qo'shma Shtatlardagi buyrak va metabolik kasalliklar bilan yashovchi odamlar uchun davolash usullarini aniqlaydi, ishlab chiqadi va etkazib beradi. Kompaniya mahsulotlari orasida FILSPARI (sparsentan) bor, bu IgA nefropatiyasining (endotelin 1 va angiotensin-II) rivojlanishining ikkita muhim yo'nalishiga qaratilgan bir kunlik og'iz orqali yuboriladigan dori; va siydikda yuqori sistin darajasiga va takrorlanuvchi buyrak toshlarining hosil bo'lishiga olib keladigan kam uchraydigan genetik sistin transport buzilishi bo'lgan sistinuriyani davolash uchun Thiola va Thiola EC (tiopronin tabletkalari). Uning klinik bosqichidagi dasturlari Sparsentan, AQSh va Evropada fokal segmental glomerulosklerozni davolash uchun Orfan dori maqomiga ega bo'lgan yangi tadqiqot mahsuloti nomzodini va klassik homosistinuriyani davolash uchun baholanayotgan yangi tadqiqot inson fermentini almashtirish nomzodi Pegtibatinase'ni o'z ichiga oladi. U sistinuriya dasturi bilan bog'liq preclinical tadbirlar uchun PharmaKrysto Limited bilan hamkorlik shartnomasiga ega. Travere Therapeutics, Inc. ilgari Retrophin, Inc. nomi bilan tanilgan va 2020-yil noyabr oyida Travere Therapeutics, Inc. nomini o'zgartirgan. Kompaniyaning shtab-kvartirasi San-Diego, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Eric M. Dube Ph.D. | President, CEO & Director |
| Dr. Jula Inrig M.D. | Chief Medical Officer |
| Dr. William E. Rote Ph.D. | Chief Research Officer |
| Mr. Casey Logan | Chief Business Officer |
| Mr. Christopher Cline C.F.A. | Chief Financial Officer |
| Mr. Peter Heerma | Chief Commercial Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-11 | 8-K | d38424d8k.htm |
| 2026-05-07 | 305B2 | d141521d305b2.htm |
| 2026-05-04 | 10-Q | tvtx-20260331.htm |
| 2026-04-14 | 8-K | tvtx-20260413.htm |
| 2026-04-06 | DEFA14A | tvtx-2026proxynoticeaccess.htm |
| 2026-04-06 | DEF 14A | tvtx-20260404.htm |
| 2026-02-19 | 10-K | tvtx-20251231.htm |
| 2026-01-13 | 8-K | tvtx-20260113.htm |
| 2026-01-12 | 8-K | tvtx-20260112.htm |
| 2025-10-30 | 10-Q | tvtx-20250930.htm |
| Ms. Angela Giannantonio |
| Chief People Officer |
| Ms. Elizabeth E. Reed J.D. | Chief Legal Officer, General Counsel & Secretary |
| Ms. Nivi Nehra | Vice President of Corporate Communications & Investor Relations |
| Ms. Sandra Calvin | SVP, Corporate Controller & Chief Accounting Officer |